Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
18 June 2019 - 10:27PM
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that Ashish
Khanna, chief financial officer and chief business officer, will
present at the 2019 BMO Prescription for Success Healthcare
Conference. The presentation will take place at 11:00 a.m. ET on
June 25, 2019 at the Mandarin Oriental in New York, NY.
A live audio webcast of the event will be available on the
Investors & Media section of Aptinyx’s website
at https://ir.aptinyx.com. A replay of the webcast will be
archived on Aptinyx’s website for 30 days following the event.
About AptinyxAptinyx Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development, and commercialization of proprietary synthetic small
molecules for the treatment of brain and nervous system
disorders. Aptinyx has a platform for discovery of novel
compounds that work through a unique mechanism to modulate—rather
than block or over-activate—NMDA receptors and enhance synaptic
plasticity, the foundation of neural cell communication. The
company has three product candidates in clinical development in
central nervous system indications, including chronic pain,
post-traumatic stress disorder, and cognitive impairment associated
with Parkinson’s disease. Aptinyx is also advancing
additional compounds from its proprietary discovery platform, which
continues to generate a rich and diverse pipeline of small-molecule
NMDA receptor modulators with the potential to treat an array of
neurologic disorders. For more information,
visit www.aptinyx.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the company’s business plans and
objectives, therapeutic effects of the company’s product
candidates, expectations regarding the design, implementation,
timing, and success of its current and planned clinical studies,
and expectations regarding its uses and sufficiency of capital.
Risks that contribute to the uncertain nature of the
forward-looking statements include: the success, cost, and timing
of the company’s product candidate development activities and
planned clinical studies; the company’s ability to execute on its
strategy; positive results from a clinical study may not
necessarily be predictive of the results of future or ongoing
clinical studies; regulatory developments in the United States and
foreign countries; as well as those risks and uncertainties set
forth in the company’s most recent Annual Report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Investor & Media Contact:Nick SmithAptinyx
Inc.ir@aptinyx.com or corporate@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2024 to May 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From May 2023 to May 2024